Altamira Therapeutics (CYTO) Stock Price, News & Analysis

Company Overview

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Key Stats

• Today's Range: $0.30 to $0.43
• 50-Day Range: $0.30 to $0.52
• 52-Week Range: $0.30 to $1.53
• Volume: 753,013 shs
• Average Volume: 313,538 shs
• Market Capitalization: $1.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYTO Stock Analysis - Frequently Asked Questions

When did Altamira Therapeutics' stock split?

Altamira Therapeutics's stock reverse split on Wednesday, December 13th 2023.The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Altamira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Altamira Therapeutics investors own include Plug Power (PLUG), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), Chemomab Therapeutics (CMMB), CNS Pharmaceuticals (CNSP), Cara Therapeutics (CARA) and Draganfly (DPRO).

Company Calendar

• Today: 7/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTO
• CIK: 1601936
• Web: www.aurismedical.com
• Phone: (441) 295-5950
• Fax: 41-61-201-1351
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $320 thousand
• Price / Sales: 3.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.56 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 3,400,000
• Free Float: 2,958,000
• Market Cap: $1.02 million
• Optionable: Not Optionable
• Beta: 1.80